ACR-368
Phase 2Small molecule
ACR-368 is one of 7 small molecule programs targeting Endometrial Adenocarcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in Endometrial Adenocarcinoma
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 2
Truqap
AstraZenecaPhase 2
Lynparza
AstraZenecaPhase 2
Gemzar
Johnson & JohnsonPhase 2
Recentin
NNational Cancer Institute (NCI)
Phase 2
ACR-368
AAcrivon Therapeutics
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ACR-368. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAcrivon Therapeutics